US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
BRPI0508830B8
(en)
*
|
2004-03-16 |
2021-05-25 |
Boehringer Ingelheim Int |
benzene derivatives substituted by glucopyranosyl, drugs containing these compounds, their use and process for their manufacture
|
US7393836B2
(en)
*
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
JP2008508213A
(en)
*
|
2004-07-27 |
2008-03-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
D-glucopyranosyl-phenyl-substituted cyclics, pharmaceuticals containing such compounds, their use and methods for their production
|
DE102004048388A1
(en)
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-pyranosyl-substituted phenyls, pharmaceutical compositions containing them, their use and processes for their preparation
|
DE102004054054A1
(en)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
|
ES2314743T3
(en)
|
2004-12-16 |
2009-03-16 |
Boehringer Ingelheim International Gmbh |
BENEFIT DERIVATIVES REPLACED WITH GLUCOPIRANOSIL, MEDICATIONS CONTAINING THIS TYPE OF COMPOUNDS, ITS USE AND PROCEDURE FOR MANUFACTURING.
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
DE602006009772D1
(en)
|
2005-02-23 |
2009-11-26 |
Boehringer Ingelheim Int |
GLUCOPYRANOSYL SUBSITUTED ((HETERO) ARYLETHYNYL-BENZYL) BenzenesIVIVES AND THEIR USE AS INHIBITORS OF SODIUM-DEPENDENT GLUCOSE COTRANSPORTER TYPE 2 (SGLT2)
|
EP1874787B1
(en)
*
|
2005-04-15 |
2009-12-30 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
|
US7723309B2
(en)
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
UA91546C2
(en)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Crystalline form of 1-chloro-4-(я-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
US7772191B2
(en)
*
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
TW200726755A
(en)
*
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
TW200733966A
(en)
*
|
2005-07-27 |
2007-09-16 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
DE102005035891A1
(en)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
|
ATE484499T1
(en)
*
|
2005-08-30 |
2010-10-15 |
Boehringer Ingelheim Int |
GLUCOPYRANOSYL-SUBSTITUTED BENZYL DERIVATIVES, MEDICATIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PRODUCTION METHOD THEREOF
|
AU2006289093A1
(en)
*
|
2005-09-08 |
2007-03-15 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
AR056195A1
(en)
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
PROCEDURES TO PREPARE DERIVATIVES OF (ETINIL-BENCIL) -BENZENE REPLACED GLUCOPYRANOSIL AND INTERMEDIATE COMPOUNDS OF THE SAME
|
ES2369016T3
(en)
*
|
2006-02-15 |
2011-11-24 |
Boehringer Ingelheim International Gmbh |
BENZONITRILE DERIVATIVES REPLACED BY GLUCOPIRANOSIL, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH TYPES OF COMPOUNDS, THEIR USE AND PROCEDURE FOR MANUFACTURING.
|
JP2009531291A
(en)
|
2006-02-15 |
2009-09-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing these compounds, their use and methods of manufacture
|
PE20080697A1
(en)
*
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
BENZONITRILE DERIVATIVES SUBSTITUTED WITH GLUCOPYRANOSIL, PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS OF THIS TYPE, THEIR USE AND PROCEDURE FOR THEIR MANUFACTURE
|
CA2810839A1
(en)
|
2006-05-04 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
|
PE20110235A1
(en)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
NZ573687A
(en)
|
2006-05-19 |
2010-10-29 |
Taisho Pharmaceutical Co Ltd |
C-phenyl glycitol compound for the treatment of diabetes
|
US7803778B2
(en)
*
|
2006-05-23 |
2010-09-28 |
Theracos, Inc. |
Glucose transport inhibitors and methods of use
|
TWI403516B
(en)
|
2006-07-27 |
2013-08-01 |
Chugai Pharmaceutical Co Ltd |
To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
|
TWI432446B
(en)
|
2006-07-27 |
2014-04-01 |
Chugai Pharmaceutical Co Ltd |
Fused ring spiroketal derivative and use thereof as anti-diabetic drug
|
US8039441B2
(en)
|
2006-08-15 |
2011-10-18 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
|
PL2066344T3
(en)
|
2006-09-07 |
2011-10-31 |
Glaxosmithkline Biologicals Sa |
Inactivated Poliovirus combination vaccine
|
US9308198B2
(en)
|
2006-09-08 |
2016-04-12 |
Rhode Island Hospital |
Treatment, prevention, and reversal of alcohol-induced brain disease
|
EP2074130A1
(en)
*
|
2006-09-21 |
2009-07-01 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
TWI499414B
(en)
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
Inhibitors of sodium glucose co-transporter 2 and methods of their use
|
JPWO2008044762A1
(en)
|
2006-10-13 |
2010-02-18 |
中外製薬株式会社 |
Thioglucose spiroketal derivatives and their use as therapeutics for diabetes
|
JP2010507629A
(en)
*
|
2006-10-27 |
2010-03-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Crystalline form of 4- (β-D-glucopyranos-1-yl) -1-methyl-2- [4-((S) -tetrahydrofuran-3-yloxy) -benzyl] -benzene, its production method and pharmaceutical preparation Use to
|
CL2007003187A1
(en)
*
|
2006-11-06 |
2008-03-07 |
Boehringer Ingelheim Int |
COMPOUNDS DERIVED FROM BENCIL-BENZONITRILE SUBSTITUTED WITH GLUCOPIRANOSIL AND ITS SALTS; PREPARATION PROCEDURE; INTERMEDIARY COMPOUNDS; PROCESS TO PREPARE INTERMEDIATE COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF
|
CA2669043A1
(en)
*
|
2006-11-09 |
2008-05-15 |
Boehringer Ingelheim International Gmbh |
Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
|
US8198464B2
(en)
|
2006-12-21 |
2012-06-12 |
Astellas Pharma Inc. |
Method for producing C-glycoside derivative and intermediate for synthesis thereof
|
US7795228B2
(en)
*
|
2006-12-28 |
2010-09-14 |
Theracos, Inc. |
Spiroheterocyclic glycosides and methods of use
|
EP2382972A1
(en)
|
2007-01-26 |
2011-11-02 |
Boehringer Ingelheim International GmbH |
Methods for preventing and treating neurodegenerative disorders
|
WO2008101938A1
(en)
*
|
2007-02-21 |
2008-08-28 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
|
JP2010519273A
(en)
|
2007-02-21 |
2010-06-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Tetrasubstituted glucopyranosylated benzene derivatives, drugs containing such compounds, their use and methods for their production
|
WO2008109591A1
(en)
*
|
2007-03-08 |
2008-09-12 |
Lexicon Pharmaceuticals, Inc. |
Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
|
EP2064222B1
(en)
|
2007-04-02 |
2014-05-07 |
Theracos, Inc. |
Benzylic glycoside derivatives and methods of use
|
CL2008002427A1
(en)
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus.
|
AU2008288770B2
(en)
*
|
2007-08-23 |
2014-06-12 |
Theracosbio, Llc |
Benzylbenzene derivatives and methods of use
|
PT2200606T
(en)
*
|
2007-09-10 |
2017-12-13 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt
|
JP5498392B2
(en)
*
|
2007-11-30 |
2014-05-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
1,5-Dihydro-pyrazolo [3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators for the treatment of CNS disorders
|
UA101004C2
(en)
*
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
CL2008003653A1
(en)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition.
|
JP5302900B2
(en)
*
|
2008-01-31 |
2013-10-02 |
アステラス製薬株式会社 |
Pharmaceutical composition for the treatment of fatty liver disease
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
PE20140960A1
(en)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
FORMULATIONS INVOLVING A DPP4 INHIBITOR
|
CA2725047A1
(en)
|
2008-05-22 |
2009-11-26 |
Bristol-Myers Squibb Company |
Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
|
BRPI0916769A2
(en)
|
2008-07-15 |
2017-09-26 |
Theracos Inc |
deuterated benzylbenzene derivatives and methods of use
|
UY32030A
(en)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
|
KR20200118243A
(en)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
Treatment for diabetes in patients inappropriate for metformin therapy
|
HUE029970T2
(en)
|
2008-08-22 |
2017-04-28 |
Theracos Sub Llc |
Processes for the preparation of sglt2 inhibitors
|
RS52236B
(en)
*
|
2008-08-28 |
2012-10-31 |
Pfizer Inc. |
Dioxa-bicyclo(3.2.1)octane-2,3,4-triol derivatives
|
NZ590788A
(en)
|
2008-09-08 |
2012-11-30 |
Boehringer Ingelheim Int |
Pyrazolopyrimidines and their use for the treatment of cns disorders
|
US8513264B2
(en)
|
2008-09-10 |
2013-08-20 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
US9056850B2
(en)
*
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
AU2009331471B2
(en)
|
2008-12-23 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Salt forms of organic compound
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
EP2395968B1
(en)
*
|
2009-02-13 |
2024-01-17 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
|
UY32427A
(en)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME
|
SG173619A1
(en)
*
|
2009-02-13 |
2011-09-29 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
|
JP5896276B2
(en)
*
|
2009-02-13 |
2016-03-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
SGLT-2 inhibitor for the treatment of type 1 diabetes, type 2 diabetes, impaired glucose tolerance or hyperglycemia
|
MX2011010184A
(en)
*
|
2009-03-31 |
2011-10-28 |
Boehringer Ingelheim Int |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators.
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
WO2011003976A1
(en)
|
2009-07-10 |
2011-01-13 |
Janssen Pharmaceutica Nv |
CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL] BENZENE
|
AR077859A1
(en)
*
|
2009-08-12 |
2011-09-28 |
Boehringer Ingelheim Int |
COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
|
SI2480559T1
(en)
|
2009-09-21 |
2013-10-30 |
Gilead Sciences, Inc. |
Processes and intermediates for the preparation of 1'-cyano-carbanucleoside analogs
|
HUE029381T2
(en)
|
2009-09-30 |
2017-02-28 |
Boehringer Ingelheim Int |
Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
|
BR112012007085B8
(en)
|
2009-09-30 |
2021-05-25 |
Boehringer Ingelheim Int |
processes for the preparation of glycopyranosyl substituted benzyl-benzene derivatives
|
US10610489B2
(en)
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
CA2777528C
(en)
*
|
2009-10-14 |
2018-09-18 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt2
|
ES2527179T3
(en)
|
2009-11-02 |
2015-01-21 |
Pfizer Inc. |
Dioxa-bicyclo derivatives [3.2.1] octane-2,3,4-triol
|
KR20240090632A
(en)
|
2009-11-27 |
2024-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
EP2368552A1
(en)
|
2010-03-25 |
2011-09-28 |
Boehringer Ingelheim Vetmedica GmbH |
1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
|
JP2013523681A
(en)
*
|
2010-03-30 |
2013-06-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Pharmaceutical composition comprising SGLT2 inhibitor and PPAR-gamma agonist and use thereof
|
EP2556056A1
(en)
|
2010-04-06 |
2013-02-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
CN102946875A
(en)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
Combination therapy
|
WO2011143296A1
(en)
|
2010-05-11 |
2011-11-17 |
Janssen Pharmaceutica Nv |
Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
CA2803504C
(en)
|
2010-06-24 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
A combination for diabetes therapy comprising linagliptin and a long-acting insulin
|
ES2524356T3
(en)
|
2010-07-22 |
2014-12-05 |
Gilead Sciences, Inc. |
Methods and compounds to treat infections caused by Paramyxoviridae virus
|
CN105541849B
(en)
|
2010-08-12 |
2018-03-23 |
勃林格殷格翰国际有限公司 |
The ketone derivatives of the dihydro-pyrazolo of 6 cycloalkyl 1,5 [3,4 d] pyrimidine 4 and its purposes as PDE9A inhibitor
|
WO2012025857A1
(en)
|
2010-08-23 |
2012-03-01 |
Hetero Research Foundation |
Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
|
CA2812061A1
(en)
|
2010-09-22 |
2012-03-29 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
CN102453026A
(en)
*
|
2010-10-27 |
2012-05-16 |
上海艾力斯医药科技有限公司 |
C-aryl glucoside derivative, preparation method and application thereof
|
BR112013010021A2
(en)
|
2010-11-02 |
2019-09-24 |
Boehringer Ingelheim Int |
pharmaceutical combinations for the treatment of metabolic disorders.
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
EP2676965B1
(en)
|
2011-02-18 |
2017-10-04 |
Shanghai Yingli Pharmaceutical Co., Ltd |
Aryl glycoside compound, preparation method and use thereof
|
UY33937A
(en)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
|
WO2012135570A1
(en)
|
2011-04-01 |
2012-10-04 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
PL2697218T3
(en)
|
2011-04-13 |
2016-11-30 |
|
Process for the preparation of compounds useful as inhibitors of sglt2
|
US20140066369A1
(en)
|
2011-04-19 |
2014-03-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012145603A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US20140051714A1
(en)
|
2011-04-22 |
2014-02-20 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
TWI542596B
(en)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
L-proline and citric acid co-crystals of (2s,3r,4r,5s,6r)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
|
CA2837627A1
(en)
*
|
2011-06-03 |
2012-12-06 |
Boehringer Ingelheim International Gmbh |
Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2013000275A1
(en)
|
2011-06-25 |
2013-01-03 |
山东轩竹医药科技有限公司 |
C-glycoside derivatives
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
DK2731947T3
(en)
|
2011-07-15 |
2019-04-23 |
Boehringer Ingelheim Int |
SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
RU2500407C2
(en)
*
|
2012-02-20 |
2013-12-10 |
Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации |
Diuretic agent
|
RU2517091C2
(en)
*
|
2012-02-20 |
2014-05-27 |
Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации) |
Medication, possessing diuretic action
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
EP2846797A1
(en)
|
2012-05-09 |
2015-03-18 |
Boehringer Ingelheim International GmbH |
Pharmaceutical combinations for the treatment of metabolic disorders
|
EP2849755A1
(en)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
US9145434B2
(en)
*
|
2012-07-26 |
2015-09-29 |
Boehringer Ingelheim International Gmbh |
Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
CN103864737B
(en)
*
|
2012-12-17 |
2016-08-17 |
天津药物研究院 |
Phenyl C-glucoside derivative containing deoxyglucose structure and its production and use
|
CN103910769B
(en)
|
2012-12-31 |
2018-10-02 |
上海璎黎药业有限公司 |
The compound of glucosan derivative and proline, crystal, preparation method and application
|
EP3466431B1
(en)
|
2013-03-14 |
2023-11-15 |
MSD International GmbH |
Crystalline forms and methods for preparing sglt2 inhibitors
|
WO2014161836A1
(en)
|
2013-04-04 |
2014-10-09 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in equine animals
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
PT2981271T
(en)
|
2013-04-05 |
2019-02-19 |
Boehringer Ingelheim Int |
Therapeutic uses of empagliflozin
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
WO2014170383A1
(en)
|
2013-04-18 |
2014-10-23 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
CN104250272B
(en)
*
|
2013-06-27 |
2018-10-09 |
上海方楠生物科技有限公司 |
A method of it is prepared using microreactor and arranges net class pharmaceutical intermediate
|
CN105611920B
(en)
|
2013-10-12 |
2021-07-16 |
泰拉科斯萨普有限责任公司 |
Preparation of hydroxy-diphenylmethane derivatives
|
US20160280619A1
(en)
*
|
2013-10-31 |
2016-09-29 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
|
EP3862003B1
(en)
|
2013-12-17 |
2023-10-25 |
Boehringer Ingelheim Vetmedica GmbH |
An sglt-2 inhibitor for use in the treatment of a metabolic disorder in feline animals
|
WO2015101916A1
(en)
|
2013-12-30 |
2015-07-09 |
Mylan Laboratories Ltd. |
Process for the preparation of empagliflozin
|
ES2593050T3
(en)
|
2014-01-03 |
2016-12-05 |
Xuanzhu Pharma Co., Ltd. |
Optically pure benzyl-4-chlorophenyl-C-glycoside derivatives as inhibitors of SGLT (diabetes mellitus)
|
US9315438B2
(en)
|
2014-01-03 |
2016-04-19 |
Xuanzhu Pharma Co., Ltd |
Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
|
CN106349201B
(en)
*
|
2014-01-03 |
2018-09-18 |
山东轩竹医药科技有限公司 |
The C- glycosides derivatives of optically pure benzyl -4- chlorphenyls
|
PL3096765T3
(en)
*
|
2014-01-23 |
2019-05-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in canine animals
|
CN103739581B
(en)
*
|
2014-01-23 |
2016-11-23 |
中国药科大学 |
C-aryl glucoside SGLT2 inhibitor
|
CN104861002A
(en)
*
|
2014-02-26 |
2015-08-26 |
天津药物研究院 |
3,6-anhydroglucose structure-containing phenyl C-glucoside derivatives and their preparation method and use
|
JP6615109B2
(en)
|
2014-02-28 |
2019-12-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Medical use of DPP-4 inhibitors
|
MX2016012705A
(en)
|
2014-04-01 |
2016-12-16 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in equine animals.
|
CN105001213B
(en)
*
|
2014-04-14 |
2020-08-28 |
上海迪诺医药科技有限公司 |
C-aryl glycoside derivative, pharmaceutical composition, preparation method and application thereof
|
BR112017003570A2
(en)
|
2014-09-25 |
2017-12-05 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment of sglt2 inhibitors and dopamine agonists to prevent metabolic disorders in equine animals
|
TWI687432B
(en)
|
2014-10-29 |
2020-03-11 |
美商基利科學股份有限公司 |
Methods for treating filoviridae virus infections
|
DE102014018230B4
(en)
*
|
2014-12-04 |
2016-10-27 |
Mann + Hummel Gmbh |
Accumulator arrangement for a vehicle
|
EP3256482B1
(en)
*
|
2015-02-09 |
2019-11-27 |
Indoco Remedies Limited |
Process for the preparation of sglt inhibitor compounds
|
CZ2015110A3
(en)
|
2015-02-18 |
2016-08-31 |
Zentiva, K.S. |
Empagliflozin solid forms
|
KR20220070057A
(en)
|
2015-03-09 |
2022-05-27 |
인테크린 테라퓨틱스, 아이엔씨. |
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
|
CZ2015279A3
(en)
|
2015-04-24 |
2016-11-02 |
Zentiva, K.S. |
Amorphous empagliflozin solid forms
|
CN106336403A
(en)
*
|
2015-07-14 |
2017-01-18 |
江苏豪森药业集团有限公司 |
Industrial preparation method for empagliflozin
|
WO2017032799A1
(en)
|
2015-08-27 |
2017-03-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Liquid pharmaceutical compositions comprising sglt-2 inhibitors
|
EP3349762B1
(en)
|
2015-09-15 |
2021-08-25 |
Laurus Labs Limited |
Co-crystals of sglt2 inhibitors, process for their preparation and pharmaceutical compositions thereof
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
HUE058737T2
(en)
|
2015-09-16 |
2022-09-28 |
Gilead Sciences Inc |
Methods for treating arenaviridae virus infections
|
JP2018530592A
(en)
*
|
2015-10-15 |
2018-10-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
SGLT-2 inhibitor for use in the treatment of metabolic myopathy
|
RU2614142C1
(en)
*
|
2016-01-14 |
2017-03-23 |
Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский политехнический университет" |
Method for production of meta-chlorobenzhydrylamine - semi-product in synthesis of anticonvulsant preparation galodif
|
US10913762B2
(en)
*
|
2016-01-27 |
2021-02-09 |
Msn Laboratories Private Limited |
Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof
|
WO2017141202A1
(en)
*
|
2016-02-17 |
2017-08-24 |
Lupin Limited |
Complex of sglt2 inhibitor and process for preparation thereof
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
CN107641139A
(en)
*
|
2016-07-22 |
2018-01-30 |
江苏豪森药业集团有限公司 |
Crystal formation of Dapagliflozin intermediate and preparation method thereof
|
EP3526229B1
(en)
|
2016-10-13 |
2021-04-28 |
Boehringer Ingelheim International GmbH |
Process for preparing glucopyranosyl-substituted benzyl-benzene derivatives
|
EP3528800A1
(en)
|
2016-10-19 |
2019-08-28 |
Boehringer Ingelheim International GmbH |
Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
|
JP2019533709A
(en)
|
2016-11-10 |
2019-11-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Pharmaceutical composition, therapeutic method and use thereof
|
CN108285439B
(en)
*
|
2017-01-09 |
2023-05-02 |
江苏天士力帝益药业有限公司 |
Carbonoside sodium glucose transport protein body 2 inhibitor
|
WO2018163194A1
(en)
*
|
2017-03-10 |
2018-09-13 |
Msn Laboratories Private Limited, R&D Center |
A process for the preparation of d-glucitol, 1,5-anhydro-1-c-[4-chloro-3-[[4- [[(3s)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, ( 1 s)
|
CN116036112A
(en)
|
2017-03-14 |
2023-05-02 |
吉利德科学公司 |
Methods for treating feline coronavirus infection
|
JP2020515639A
(en)
|
2017-04-03 |
2020-05-28 |
コヒラス・バイオサイエンシズ・インコーポレイテッド |
PPARγ agonists for the treatment of progressive supranuclear palsy
|
ES2938859T3
(en)
|
2017-05-01 |
2023-04-17 |
Gilead Sciences Inc |
A crystalline form of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4 ]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
|
US11312740B2
(en)
|
2017-05-09 |
2022-04-26 |
Piramal Pharma Limited |
Process for the preparation of SGLT2 inhibitors and intermediates thereof
|
ES2958820T3
(en)
|
2017-06-05 |
2024-02-15 |
Laurus Labs Ltd |
New procedure for the preparation of empagliflozin or its cocrystals, solvates and its polymorphs
|
CN107163092B
(en)
*
|
2017-06-13 |
2020-05-19 |
杭州科巢生物科技有限公司 |
Preparation method of SGLT-2 diabetes inhibitor and intermediate thereof
|
JP7174757B2
(en)
*
|
2017-07-04 |
2022-11-17 |
イントゥーセル,インコーポレーティッド |
Compounds containing cleavable linkers and uses thereof
|
CN117982682A
(en)
|
2017-07-11 |
2024-05-07 |
吉利德科学公司 |
Compositions comprising an RNA polymerase inhibitor and a cyclodextrin for treating viral infections
|
EP3762379A1
(en)
|
2018-03-07 |
2021-01-13 |
Bayer Aktiengesellschaft |
Identification and use of erk5 inhibitors
|
JP2021520394A
(en)
|
2018-04-17 |
2021-08-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Pharmaceutical composition, treatment method and its use
|
CZ2018188A3
(en)
|
2018-04-18 |
2019-10-30 |
Zentiva, K.S. |
Amorphous empagliflozin particles, process for preparing them and pharmaceutical preparation
|
CN110117300A
(en)
*
|
2018-04-23 |
2019-08-13 |
中国科学院成都生物研究所 |
Medicinal usage comprising white 1 inhibitor of sodium glucose co-transporter 2
|
CN108610385A
(en)
*
|
2018-04-23 |
2018-10-02 |
中国科学院成都生物研究所 |
A kind of medicinal usage of white 1 inhibitor of sodium glucose co-transporter 2
|
KR102204439B1
(en)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Pharmaceutical Composition comprising SGLT-2 inhibitor and DPP-IV inhibitor
|
CN108774275A
(en)
*
|
2018-07-16 |
2018-11-09 |
西北大学 |
The method of the full acetyl group-α-O- benzyls sugar of one-step synthesis
|
EP3823631A1
(en)
|
2018-07-19 |
2021-05-26 |
Astrazeneca AB |
Methods of treating hfpef employing dapagliflozin and compositions comprising the same
|
WO2020020896A1
(en)
|
2018-07-25 |
2020-01-30 |
Boehringer Ingelheim International Gmbh |
Empagliflozin for use in treating alport syndrome
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
WO2020050361A1
(en)
*
|
2018-09-06 |
2020-03-12 |
株式会社トクヤマ |
PRODUCTION METHOD FOR β-C-ARYL GLYCOSIDE DERIVATIVE
|
WO2020084560A1
(en)
*
|
2018-10-26 |
2020-04-30 |
Janssen Pharmaceutica Nv |
Glucopyranose derivatives useful as sglt2 inhibitors
|
WO2020242253A1
(en)
*
|
2019-05-30 |
2020-12-03 |
동아에스티 주식회사 |
Novel empagliflozin derivative which is sglt-2 inhibitor
|
CN112047915B
(en)
*
|
2019-06-05 |
2023-02-17 |
北京惠之衡生物科技有限公司 |
Novel preparation process of C-glycoside derivatives
|
AU2020310274B2
(en)
*
|
2019-07-05 |
2022-09-29 |
Shandong Danhong Pharmaceutical Co., Ltd. |
Crystal form of SGLT inhibitor and application thereof
|
EP4005568B1
(en)
*
|
2019-07-26 |
2024-07-10 |
Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. |
Sglts/dpp4 inhibitor and application thereof
|
EP4064854A1
(en)
|
2019-11-28 |
2022-10-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors in the drying-off of non-human mammals
|
WO2021123165A1
(en)
|
2019-12-19 |
2021-06-24 |
Krka, D.D., Novo Mesto |
Dosage form comprising amorphous solid solution of empagliflozin with polymer
|
KR102111248B1
(en)
|
2019-12-30 |
2020-05-14 |
유니셀랩 주식회사 |
New Empagliflozin cocrystal
|
JP2023512656A
(en)
|
2020-01-27 |
2023-03-28 |
ギリアード サイエンシーズ, インコーポレイテッド |
Methods for treating SARS CoV-2 infection
|
MX2022010090A
(en)
|
2020-02-17 |
2022-09-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines.
|
BR112022017189A2
(en)
|
2020-03-06 |
2022-10-18 |
Vertex Pharma |
METHODS OF TREATMENT OF APOL-1 DEPENDENT FOCAL SEGMENTARY GLOMERULOSCLEROSIS
|
CA3169340A1
(en)
|
2020-03-12 |
2021-09-16 |
Pavel R. Badalov |
Methods of preparing 1'-cyano nucleosides
|
KR102207319B1
(en)
|
2020-03-23 |
2021-01-25 |
유니셀랩 주식회사 |
New Empagliflozin cocrystal
|
KR102150825B1
(en)
|
2020-04-06 |
2020-09-03 |
유니셀랩 주식회사 |
Novel sglt-2 inhibitors cocrystal
|
CA3172483A1
(en)
|
2020-04-06 |
2021-10-14 |
Scott Ellis |
Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
|
JP2023520899A
(en)
|
2020-04-07 |
2023-05-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Methods for treatment of headache disorders
|
EP4138826A1
(en)
|
2020-04-22 |
2023-03-01 |
Bayer Aktiengesellschaft |
Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
|
US11975012B2
(en)
|
2020-05-29 |
2024-05-07 |
Gilead Sciences, Inc. |
Remdesivir treatment methods
|
WO2021250565A1
(en)
*
|
2020-06-10 |
2021-12-16 |
Hikal Limited |
An improved process for preparation of empagliflozin and its crystalline polymorph
|
AU2021296841A1
(en)
|
2020-06-24 |
2023-02-16 |
Gilead Sciences, Inc. |
1'-cyano nucleoside analogs and uses thereof
|
WO2022011239A1
(en)
*
|
2020-07-10 |
2022-01-13 |
Rosalind Franklin University Of Medicine And Science |
Gliflozins and a method for their delivery during resuscitation from cardiac arrest to improve survival outcomes
|
WO2022022865A1
(en)
|
2020-07-27 |
2022-02-03 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
PT4204421T
(en)
|
2020-08-27 |
2024-06-25 |
Gilead Sciences Inc |
Compounds and methods for treatment of viral infections
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
KR20220068805A
(en)
|
2020-11-19 |
2022-05-26 |
한미약품 주식회사 |
Novel glucose derivatives
|
EP4023644A1
(en)
|
2020-12-30 |
2022-07-06 |
Zaklady Farmaceutyczne Polpharma SA |
Process for the preparation of a pharmaceutical agent
|
WO2022160737A1
(en)
*
|
2021-01-26 |
2022-08-04 |
东宝紫星(杭州)生物医药有限公司 |
Crystal form of tetrahydropyran ring compound and preparation method therefor
|
EP4315350A1
(en)
|
2021-04-01 |
2024-02-07 |
AstraZeneca UK Limited |
Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
|
MX2024001184A
(en)
|
2021-07-28 |
2024-02-27 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines.
|
US20240307426A1
(en)
|
2021-07-28 |
2024-09-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
|
EP4376819A1
(en)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
CN113773194B
(en)
|
2021-08-16 |
2023-05-02 |
浙江奥翔药业股份有限公司 |
Preparation method of 5-bromo-2-chloro-benzoic acid as synthesis raw material of hypoglycemic agent
|
IL314031A
(en)
|
2021-12-30 |
2024-09-01 |
Newamsterdam Pharma B V |
Obicetrapib and sglt2 inhibitor combination
|
WO2023144722A1
(en)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|
EP4320128A1
(en)
|
2022-03-02 |
2024-02-14 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
WO2023213715A1
(en)
|
2022-05-04 |
2023-11-09 |
Société des Produits Nestlé S.A. |
Ampk activator (cbda) and sglt2 inhibitor for metabolic health
|
WO2023227492A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
WO2024033288A1
(en)
|
2022-08-12 |
2024-02-15 |
Société des Produits Nestlé S.A. |
Salicin derivatives as inhibitors of sglt2
|
WO2024033287A1
(en)
|
2022-08-12 |
2024-02-15 |
Société des Produits Nestlé S.A. |
Hydroxycholest-5-ene glycosides as inhibitors of sglt2
|
WO2024038011A1
(en)
|
2022-08-18 |
2024-02-22 |
Société des Produits Nestlé S.A. |
Methylated phloretin analogs as inhibitors of sglt2
|
WO2024056498A1
(en)
|
2022-09-12 |
2024-03-21 |
Société des Produits Nestlé S.A. |
Oxindole alkaloid derivatives as inhibitors of sglt2
|
WO2024068511A1
(en)
|
2022-09-28 |
2024-04-04 |
Société des Produits Nestlé S.A. |
Diterpenoid derivatives as inhibitors of sglt2
|
EP4378455A1
(en)
|
2022-11-29 |
2024-06-05 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A pharmaceutical formulation comprising empagliflozin
|
EP4420658A1
(en)
|
2023-02-24 |
2024-08-28 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A film coated tablet comprising empagliflozin
|
WO2024184293A1
(en)
|
2023-03-06 |
2024-09-12 |
Boehringer Ingelheim Vetmedica Gmbh |
Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
|